The European Commission, upon proposal from the European Medicines Agency (EMA), has designated Gefitinib as an orphan drug for Fanconi anemia. This orally administered product is currently indicated for the treatment of lung cancer. The studies...
Read more
Dr. Simó Schwartz Jr, head of the CIBBIM-Nanomedicine Drug Delivery and Targeting group, Dr. Diego Arango, head of the CIBBIM-Nanomedicine Biomedical Research in Digestive Tumors group, and Dr. Mar Hernández-Guillamón, principal investigator of...
Read more
The Vall d’Hebron Research Institute (VHIR) has received two projects in the last call of the Associación Española Contra el Cáncer (AECC) to investigate stomach cancer and malignant melanoma. The projects, worth 1,200,000 euros each, are...
Read more
Researchers from the Group of Molecular Oncology CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR) have validated a gene, called PPOX, as a new therapeutic target against colorectal cancer. Furthermore, this study opens the door...
Read more
